Analysts/Institutional Investor Meet/Con. Call Updates

Ref No.: ZLL/CS/BSE/NSE Date: 12.08.2026 BSE Limited, National Stock Exchange of India Limited Corporate Relationship Department Listing Compliance Department P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai – 400 051 Company Code- 541400 (Symbol - ZIMLAB) Dear Sir/Madam, Sub: Transcript of Q1 FY27 Earnings Conference Call Dear Sir/Madam, Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), please find enclosed the transcript of Earnings Conference call for Q1 FY27 held on Friday, 07th August, 2026. The same is available on the Website of the Company at: https://drive.google.com/file/d/10Aoq9kA_1uW5a2xj5Nis7Yss4E-u-Ikt/view Request you to kindly take the same on your record. Thanking you, Yours faithfully, For ZIM LABORATORIES LIMITED (Piyush Nikhade) Company Secretary and Compliance Officer Membership No. A38972 ZIM LABORATORIES LIMITED www.zimlab.in I info@zimlab.in I CIN : L99999MH1984PLC032172 Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square, Maharashtra, India. Ph. + 91.718.271370 I Fax : +091.7118.271470 Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960 Zim Laboratories Limited Q1 FY27 Earnings Conference Call Event Date/Time : 07/08/2026, 12.00 Hrs IST Event Duration : 56 mins 59 secs MANAGEMENT DETAILS: Mr. Zulfiquar Kamal Director-Finance Mr. Shyam Mohan Patro Chief Financial Officer-Accounts & Finance Mr. Piyush Nikhade Company Secretary Mr. Zain Daud Investor Relations Ms. Priya Sen Go India Advisors Zim Laboratories Limited Q1 FY27 Earnings Conference Call 07.08.2026 Q&A PARTICIPANTS: 1 Rohit Balakrishnan : ithought PMS 2 Dipesh : Maanya Finance 3 Vishal : Individual Investor 4 Nikhil Gupta : Vaayu capital 5 Pujith Agarwal : Individual Investor 6 Nishita Shanklesha : Sapphire Capital 7 Rupesh Tatiya : Long Equity Partners 8 Madhur Rathi : Counter Cyclical Investments Zim Laboratories Limited Q1 FY27 Earnings Conference Call 07.08.2026 Moderator Good afternoon, ladies and gentlemen. I'm Akash, moderator for the conference call. Welcome to Zim Laboratories Limited Q1 FY27 Earnings Conference Call hosted by Go India Advisors. As a reminder, all participants will be in listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing * then 0 on the touch-tone telephone. Please note this conference is being recorded. I would now like to hand over the floor to Ms. Priya Sen from Go India Advisors. Thank you, and over to you, ma'am. Priya Sen Thank you, Akash. Good afternoon, everyone, and welcome to the Q1 FY27 Earnings Call of Zim Laboratories Limited. We have on the call Mr. Zulfiquar Kamal, Director-Finance; Mr. Shyam Mohan Patro, Chief Financial Officer; Mr. Zain Daud, Investor Relations; and Mr. Piyush Nikhade, Company Secretary. We must remind you that the discussion on today's call may include certain forward-looking statements and must, be therefore, viewed in conjunction with the risks that the company faces. May I now request the management to take us through the financials and the business outlook, subsequent to which we will open the floor to questions and answers. Thank you, and over to you, sir. Zulfiquar Kamal Thank you, Priya. Good afternoon, everyone. This is Zulfiquar Kamal speaking on behalf of the management team. I would like to warmly welcome you all to Zim Laboratories Limited Earnings Conference Call for the first quarter FY27. I trust you had the opportunity to review our financial results and the investor presentation, both of which have been made available on the stock exchanges. Before I discuss our business performance for the quarter, let me begin with an update on the EU-GMP remediation process, which continues to remain one of our highest strategic priorities. As you are aware, our manufacturing facilities underwent EU-GMP reinspection conducted by German and Portuguese regulatory authorities during May 26. The inspection has now been completed, and we are currently awaiting the final inspection report from the authorities. Based on the draft observations shared during the inspection process, we have already prepared a comprehensive corrective and preventive action (CAPA) plan and are ready to submit it Zim Laboratories Limited Q1 FY27 Earnings Conference Call 07.08.2026 immediately upon receipt of the final report. Over the past year, we have made significant investments to strengthen our quality systems, manufacturing processes, and compliance framework. While the regulatory process is now in the hands of the authorities, we remain confident that the extensive work undertaken over the past several months has positioned us well for a successful outcome. With the inspection now completed, we believe the company has entered the final stage of its EU-GMP remediation journey. Subject to the regulatory review process and the timelines, the successful completion of this exercise is expected to significantly strengthen our position in regulated markets and unlock meaningful growth opportunities for our innovation-led portfolio. Turning to our business performance, the first quarter reflected healthy revenue growth, supported by continued strength in our core pharmaceutical business. Our export business remained resilient despite ongoing geopolitical uncertainties in certain regions, with exports contributing approximately 84% of our total operating income during the quarter. Our EBITDA margins for the quarter were impacted by planned investments in the business. These included higher employee costs following the strengthening of our senior leadership team, increased utility, fuel and power expenses, and consulting costs associated with financing of our EU-GMP remediation program. I am also pleased to share that our new innovative product portfolio and oral insulin business returned to a normalized level of contribution during the quarter, accounting for approximately 18% of our revenue. We remain confident that this platform represents our most significant long-term growth opportunity, and our aspiration remains to increase the contribution of NIP and OTF product portfolio revenue over the coming years. Looking ahead, our priorities remain clear. We are focused on successful completing of our EU-GMP regulatory processes, expanding our innovation-led portfolio, strengthening our global customer base, and delivering substantial profitable growth. FY27 represents an important transition year for Zim Laboratories. With our compliance investments substantially behind us, strengthening leadership team in place, and our innovation pipeline ready for commercialization, we believe the company is well positioned to enter the next phase of substantial growth. With that, I would now like to hand over the call to our Chief Financial Officer, Mr. Shyam Patro, who will take you through the financial performance for the quarter in greater detail. Over to you, Shyam. Thank you. Shyam Mohan Patro Thank you, Mr. Kamal. Good afternoon, everyone. Let me now take you to the financial highlights for the first quarter ended 30th June. The earnings presentation has been uploaded on the stock exchanges, and I would like to request investors to refer to it alongside my remarks. For the first quarter FY27, the Zim Laboratories Limited Q1 FY27 Earnings Conference Call 07.08.2026 company reported total operating income of approximately INR 942 million, representing 31.2% YoY growth. EBITDA for the quarter stood at INR 34 million, translating into an EBITDA margin of 3.7%. Profit after tax for the quarter stood at minus INR 40 million compared to minus INR 19 million in the corresponding quarter of the previous year. Exports continue to account for approximately 84% of our total income. The NIP, t [Showing first 8,000 characters — download PDF for full document]